Get the Stockscreener App
4.01
2.69%
0.105
After Hours:
4.01
Newcelx Ltd stock is traded at $4.01, with a volume of 27,853.
It is up +2.69% in the last 24 hours and up +36.86% over the past month.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
See More
Previous Close:
$3.905
Open:
$4
24h Volume:
27,853
Relative Volume:
0.53
Market Cap:
$21.59M
Revenue:
-
Net Income/Loss:
$-2.17M
P/E Ratio:
-0.2312
EPS:
-17.3434
Net Cash Flow:
$-4.82M
1W Performance:
+9.56%
1M Performance:
+36.86%
6M Performance:
+73.59%
1Y Performance:
+0.00%
1-Day Range:
$3.81
$4.02
1-Week Range:
$3.40
$4.235
52-Week Range:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
4.01 | 21.02M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newcelx Ltd Stock (NCEL) Latest News
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - TipRanks
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView
NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NCEL Should I Buy - Intellectia AI
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis - TipRanks
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - The Manila Times
Peer-reviewed AstroRx data underscore NewcelX (NCEL) stem cell platform - Stock Titan
NewcelX Ltd. (NCEL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen - TipRanks
NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment - Bez Kabli
Exclusive: NewcelX advances diabetes therapy toward human trials with FDA pre-IND submission - MSN
NewcelX Ltd. (NCEL) Gains Ground: Testing Key Resistance LevelsStatistical Arbitrage - newsline.com
Newcelx submits pre-IND package for NCEL-101 to FDA - BioWorld News
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy - TipRanks
Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes - marketscreener.com
NewcelX (Nasdaq: NCEL) files FDA pre-IND for NCEL-101 diabetes cell therapy - Stock Titan
NewcelX Ltd. Schedules Pre-IND Meeting with FDA to Propel Type 1 Diabetes Treatment NCEL-101 into First-In-Human Trials - Quiver Quantitative
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
Newcelx Ltd Stock (NCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Newcelx Ltd Stock (NCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):